Using multi-criteria decision analysis to appraise orphan drugs: a systematic review

Carlotta Friedmann, Pierre Levy, Paul Hensel, Mickael Hiligsmann*

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

14 Citations (Web of Science)

Abstract

Introduction: Multi-criteria decision analysis (MCDA) could potentially solve current methodological difficulties in the appraisal of orphan drugs.Areas covered: We provide an overview of the existing evidence regarding the use of MCDA in the appraisal of orphan drugs worldwide. Three databases (Pubmed, Embase, Web of Science) were searched for English, French and German literature published between January 2000 and April 2017. Full-text articles were supplemented with conference abstracts. A total of seven articles and six abstracts were identified.Expert commentary: The literature suggests that MCDA is increasingly being used in the context of appraising orphan drugs. It has shown itself to be a flexible approach with the potential to assist in decision-making regarding reimbursement for orphan drugs. However, further research regarding its application must be conducted.
Original languageEnglish
Pages (from-to)135-146
Number of pages12
JournalExpert Review of Pharmacoeconomics & Outcomes Research
Volume18
Issue number2
DOIs
Publication statusPublished - 1 Jan 2018

Keywords

  • Multi-criteria decision analysis
  • MCDA
  • orphan drugs
  • rare diseases
  • reimbursement
  • appraisal
  • systematic review
  • HEALTH TECHNOLOGY-ASSESSMENT
  • PRACTICES TASK-FORCE
  • RARE DISEASES
  • ANALYSIS MCDA
  • REIMBURSEMENT SYSTEMS
  • EVALUATING TREATMENTS
  • EVIDEM FRAMEWORK
  • CRITERIA
  • CARE
  • CONTEXT

Cite this